Cerulean Pharma Inc. (CERU) Appoints Vice President, Clinical Operations

Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting™, today announced the appointment of Tiffany Crowell as Vice President, Clinical Operations.

"Tiffany comes to Cerulean with deep experience and demonstrated leadership in clinical development and operations that will be crucial in supporting our clinical development of CRLX101 and CRLX301," said Paul Friedman, MD, Executive Chairman of Cerulean.

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.